Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
First Claim
1. A method of treating a disease or disorder associated with reduced nicotinamide adenine dinucleotide (NAD+) levels selected from the group consisting of a metabolic disorder, a neurodegenerative disease, a chronic inflammatory disease, a fatty liver disease, and a kidney disorder in a subject, the method comprising administering to the subject suffering from or susceptible to developing a disease or disorder associated with reduced NAD+ levels a therapeutically effective amount of a compound represented by Formula (I):
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure discloses compounds capable of modulating the activity of α-amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
-
Citations
11 Claims
- 1. A method of treating a disease or disorder associated with reduced nicotinamide adenine dinucleotide (NAD+) levels selected from the group consisting of a metabolic disorder, a neurodegenerative disease, a chronic inflammatory disease, a fatty liver disease, and a kidney disorder in a subject, the method comprising administering to the subject suffering from or susceptible to developing a disease or disorder associated with reduced NAD+ levels a therapeutically effective amount of a compound represented by Formula (I):
-
2. A method of treating a disease or disorder associated with reduced nicotinamide adenine dinucleotide (NAD+) levels selected from the group consisting of a metabolic disorder, a neurodegenerative disease, a chronic inflammatory disease, a fatty liver disease, and a kidney disorder in a subject, the method comprising administering to the subject suffering from or susceptible to developing a disease or disorder associated with reduced NAD+levels a therapeutically effective amount of a compound selected from the group consisting of:
Specification